| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 23 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 平均 |
Supplementation of the standard doses of creatine during a loading phase (0.3g/kg bodyweight) and maintenance phase (0.07g/kg) failed to improve cardiovascular or muscular performance any more than placebo in persons with COPD; lung function and quality of life were similarly unaffected.
Creatine Monohydrate Enhances Strength And Body Composition In Duchenne Muscular Dystrophy
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 30 |
| 性別 | 男性 |
| 年齢 | 7-12 |
| 体型 | 肥満, 肥満 |
In thirty children given creatine supplementation at around 2-5g daily (half of which were on corticosteroids) for four months of time, supplementation of creatine was associated with an increase in strength of the dominant hand (but not the other) and an almost significant reduction in whole body strength seen in placebo was prevented with creatine.
There were no improvements on activities of daily living or lung function, and there was no influence on DNA damage as assessed by the 8-OH-2-dG/creatinine ratio (but creatinine was also unaffected).
Effects Of Creatine Supplementation On Exercise Performance And Muscular Strength In Amyotrophic Lateral Sclerosis: Preliminary Results
| 効果 | なし |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 28 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
In patients with probable/definite Amyotrophic Lateral Sclerosis (ALS), creatine monohydrate enhanced Maximal Voluntary Isometric Contraction (MVIC) significantly at the elbow (53% of subjects) and knee (70% of subjects) after the 1-week loading phase (20 g/day). However, over the 6-month maintenance phase (3 g/day), the rates of decline for both the upper and lower limbs were not statistically different from the rates of decline before treatment, suggesting no longer-term effect.
The study saw many dropouts due to initial diarrhea from the loading phase, but no abnormalities were detected in the kidney or the liver.
Creatine Monohydrate Supplementation Does Not Increase Muscle Strength, Lean Body Mass, Or Muscle Phosphocreatine In Patients With Myotonic Dystrophy Type 1
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 34 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 平均 |
5 g/day for 4 months in individuals with myotonic dystrophy type I (DM1) failed to improve muscular strength (handgrip) or lung function (FEV1) relative to placebo, nor was there any influence on functional tests or biochemical parameters.
A Randomized Sequential Trial Of Creatine In Amyotrophic Lateral Sclerosis
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ Months |
| 被験者数 | 175 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
10 g/day (5 g twice a day) for 16 months, as an adjuvant to riluzole, attenuated the loss rate of muscle strength but not of lung function. Survival was not affected to a significant extent. The treatment was well tolerated.
Creatine Monohydrate In ALS: Effects On Strength, Fatigue, Respiratory Status And ALSFRS
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ Months |
| 被験者数 | 107 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
5 g/day for 9 months (following 10 g/day for five days) failed to benefit well-being, functional capacity, lung function, or muscular capacity as assessed by Maximal Voluntary Isometric Contraction (MVIC). The treatment proved safe, however, and the risk of death was nonsignificantly reduced.
No Effect Of Creatine On Respiratory Distress In Amyotrophic Lateral Sclerosis
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 27 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
In patients with Amyotrophic Lateral Sclerosis (ALS), 5 g/day failed to benefit lung function (FEV, maximal capacity, forced vital capacity, etc.). Patients dropped out from the study when they had to go on mechanical ventilation, were unable to make their visits to the clinic due to severe motor deterioration, or died. Out of 14 patients, 9 lasted for 6 months, and only 1 for 9 months.